Abstract
Background We evaluated if interventions aimed at air travellers can delay local SARS-CoV-2 community transmission in a previously unaffected country.
Methods We simulated infected air travellers arriving into countries with no sustained SARS-CoV-2 transmission or other introduction routes from affected regions. We assessed the effectiveness of syndromic screening at departure and/or arrival & traveller sensitisation to the COVID-2019-like symptoms with the aim to trigger rapid self-isolation and reporting on symptom onset to enable contact tracing. We assumed that syndromic screening would reduce the number of infected arrivals and that traveller sensitisation reduces the average number of secondary cases. We use stochastic simulations to account for uncertainty in both arrival and secondary infections rates, and present sensitivity analyses on arrival rates of infected travellers and the effectiveness of traveller sensitisation. We report the median expected delay achievable in each scenario and an inner 50% interval.
Results Under baseline assumptions, introducing exit and entry screening in combination with traveller sensitisation can delay a local SARS-CoV-2 outbreak by 8 days (50% interval: 3-14 days) when the rate of importation is 1 infected traveller per week at time of introduction. The additional benefit of entry screening is small if exit screening is effective: the combination of only exit screening and traveller sensitisation can delay an outbreak by 7 days (50% interval: 2-13 days). In the absence of screening, with less effective sensitisation, or a higher rate of importation, these delays shrink rapidly to less than 4 days.
Conclusion Syndromic screening and traveller sensitisation in combination may have marginally delayed SARS-CoV-2 outbreaks in unaffected countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SF and SC are supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z). RME acknowledges an HDR UK Innovation Fellowship (Grant number MR/S003975/1). BQ was funded by the National Institute for Health Research (NIHR) (16/137/109) using UK aid from the UK Government to support global health research. PK was funded by the Bill & Melinda Gates Foundation (INV-003174). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the UK Department of Health and Social Care. The following authors were part of the Centre for Mathematical Modelling of Infectious Disease SARS-CoV-2 working group and contributed equally and appear in random order: Christopher I Jarvis, Yang Liu, Nikos I Bosse, Kiesha Prem, Adam J Kucharski, W John Edmunds, Timothy W Russell, Sebastian Funk, Mark Jit, Hamish Gibbs, Sam Abbott, James D Munday, Amy Gimma, Nicholas Davies, Carl AB Pearson, Charlie Diamond, Joel Hellewell. Each contributed in processing, cleaning and interpretation of data, interpreted findings, contributed to the manuscript, and approved the work for publication. We also like to thank John Edmunds, Graham Medley and Annelies Wilder-Smith for their helpful comments during the conception of this work.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The study contains no primary data
